REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
Status:
Recruiting
Trial end date:
2032-12-01
Target enrollment:
Participant gender:
Summary
Fixed-duration regimens containing combinations of venetoclax with CD20 targeting agents are
expected to soon become standard practice in first-line patients with chronic lymfocytic
leukemia (CLL). The advantage of a fixed duration venetoclax combination as part of
first-line treatment is the potential to retreat with venetoclax in patients who develop
relapsed disease after a treatment free period. However, efficacy of venetoclax retreatment
following a fixed duration venetoclax combination is still hypothetical as clinical data are
lacking. Thus, there is an urgent need for data proving efficacy of venetoclax combinations
following venetoclax treatment cessation. Testing of a novel venetoclax-containing regimen
for relapsed CLL without the repeat of anti-CD20 monoclonal antibody (mAb) is a rational
approach.
Phase:
Phase 2
Details
Lead Sponsor:
Stichting Hemato-Oncologie voor Volwassenen Nederland